Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies
Published 2010 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies
Authors
Keywords
-
Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 12, Issue 1, Pages 13-30
Publisher
Informa Healthcare
Online
2010-07-15
DOI
10.1517/14656566.2010.502529
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Narrative Review: Statin-Related Myopathy
- (2013) Tisha R. Joy ANNALS OF INTERNAL MEDICINE
- Effect of Ezetimibe on Hepatic Fat, Inflammatory Markers, and Apolipoprotein B-100 Kinetics in Insulin-Resistant Obese Subjects on a Weight Loss Diet
- (2010) D. C. Chan et al. DIABETES CARE
- A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin
- (2010) Kai-Hang Yiu et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The metabolic syndrome
- (2010) Robert H Eckel et al. LANCET
- Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials
- (2010) Naveed Sattar et al. LANCET
- Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Lipid-Altering Efficacy and Safety of Ezetimibe/Simvastatin Versus Atorvastatin in Patients With Hypercholesterolemia and the Metabolic Syndrome (from the VYMET Study)
- (2009) Jennifer G. Robinson et al. AMERICAN JOURNAL OF CARDIOLOGY
- Correlation of Non–High-Density Lipoprotein Cholesterol and Low-Density Lipoprotein Cholesterol With Apolipoprotein B During Simvastatin + Fenofibrate Therapy in Patients With Combined Hyperlipidemia (A Subanalysis of the SAFARI Trial)
- (2009) Scott M. Grundy et al. AMERICAN JOURNAL OF CARDIOLOGY
- Trajectories of Entering the Metabolic Syndrome
- (2009) Oscar H. Franco et al. CIRCULATION
- Harmonizing the Metabolic Syndrome
- (2009) K.G.M.M. Alberti et al. CIRCULATION
- Regulatory Effects of Fenofibrate and Atorvastatin on Lipoprotein A-I and Lipoprotein A-I:A-II Kinetics in the Metabolic Syndrome
- (2009) D. C. Chan et al. DIABETES CARE
- Commentary on pharmacotherapy of regional melanoma therapy
- (2009) Jonathan S Zager et al. EXPERT OPINION ON PHARMACOTHERAPY
- Non-adherence to statin therapy: a major challenge for preventive cardiology
- (2009) TR Bates et al. EXPERT OPINION ON PHARMACOTHERAPY
- Responses of LDL and HDL particle size and distribution to omega-3 fatty acid supplementation and aerobic exercise
- (2009) Joshua S. Wooten et al. JOURNAL OF APPLIED PHYSIOLOGY
- The Vytorin on Carotid Intima-Media Thickness and Overall Arterial Rigidity (VYCTOR) Study
- (2009) Alejandra Meaney et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia
- (2009) André J Tremblay et al. JOURNAL OF LIPID RESEARCH
- Effects of Niacin on Glucose Control in Patients With Dyslipidemia
- (2009) Ronald B. Goldberg et al. MAYO CLINIC PROCEEDINGS
- Extended-Release Niacin or Ezetimibe and Carotid Intima–Media Thickness
- (2009) Allen J. Taylor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Moderate-Dose Omega-3 Fish Oil on Cardiovascular Risk Factors and Mood After Ischemic Stroke
- (2009) Sally D. Poppitt et al. STROKE
- Comparison of the Safety and Efficacy of a Combination Tablet of Niacin Extended Release and Simvastatin vs Simvastatin Monotherapy in Patients With Increased Non–HDL Cholesterol (from the SEACOAST I Study)
- (2008) Christie M. Ballantyne et al. AMERICAN JOURNAL OF CARDIOLOGY
- Reducing the Residual Risk of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Therapy With Combination Therapy
- (2008) Tamar S. Polonsky et al. AMERICAN JOURNAL OF CARDIOLOGY
- Comparison of Effects of Simvastatin Alone Versus Fenofibrate Alone Versus Simvastatin Plus Fenofibrate on Lipoprotein Subparticle Profiles in Diabetic Patients With Mixed Dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen Study)
- (2008) Heidi T. May et al. AMERICAN JOURNAL OF CARDIOLOGY
- Effects of Adding Prescription Omega-3 Acid Ethyl Esters to Simvastatin (20 mg/day) on Lipids and Lipoprotein Particles in Men and Women With Mixed Dyslipidemia
- (2008) Kevin C. Maki et al. AMERICAN JOURNAL OF CARDIOLOGY
- Extended-Release Niacin Alters the Metabolism of Plasma Apolipoprotein (Apo) A-I and ApoB-Containing Lipoproteins
- (2008) Stefania Lamon-Fava et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Niacin Increases HDL by Reducing Hepatic Expression and Plasma Levels of Cholesteryl Ester Transfer Protein in APOE*3Leiden.CETP Mice
- (2008) José W.A. van der Hoorn et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Atorvastatin and Fenofibrate Have Comparable Effects on VLDL-Apolipoprotein C-III Kinetics in Men With the Metabolic Syndrome
- (2008) Dick C. Chan et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Overproduction of Very Low–Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome
- (2008) Martin Adiels et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Oxidation of chylomicron remnants and vascular dysfunction
- (2008) Kathleen M. Botham ATHEROSCLEROSIS SUPPLEMENTS
- Mechanism of intestinal lipoprotein overproduction in insulin resistant humans
- (2008) Hélène Duez et al. ATHEROSCLEROSIS SUPPLEMENTS
- Small, dense low-density lipoproteins (LDL) are predictors of cardio- and cerebro-vascular events in subjects with the metabolic syndrome
- (2008) Manfredi Rizzo et al. CLINICAL ENDOCRINOLOGY
- A single bout of whole-body resistance exercise augments basal VLDL-triacylglycerol removal from plasma in healthy untrained men
- (2008) Yiannis E. Tsekouras et al. CLINICAL SCIENCE
- Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation
- (2008) J. D. Brunzell et al. DIABETES CARE
- Effects of 20 mg rosuvastatin on VLDL1-, VLDL2-, IDL- and LDL-ApoB kinetics in type 2 diabetes
- (2008) B. Vergès et al. DIABETOLOGIA
- The Metabolic Syndrome
- (2008) Marc-Andre Cornier et al. ENDOCRINE REVIEWS
- Effect of weight loss on markers of triglyceride-rich lipoprotein metabolism in the metabolic syndrome
- (2008) D. C. Chan et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- Very Low Density Lipoprotein Metabolism and Plasma Adiponectin as Predictors of High-Density Lipoprotein Apolipoprotein A-I Kinetics in Obese and Nonobese Men
- (2008) Dick C. Chan et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials
- (2008) A. Pandor et al. JOURNAL OF INTERNAL MEDICINE
- Effect of Statins Alone Versus Statins Plus Ezetimibe on Carotid Atherosclerosis in Type 2 Diabetes
- (2008) Jerome L. Fleg et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of 6-month supervised exercise on low-density lipoprotein apolipoprotein B kinetics in patients with type 2 diabetes mellitus
- (2008) Michael Stolinski et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis
- (2008) Anne B. Rossebø et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
- (2008) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dose-dependent effect of rosuvastatin on apolipoprotein B-100 kinetics in the metabolic syndrome
- (2007) Esther M.M. Ooi et al. ATHEROSCLEROSIS
- Dose-Dependent Regulation of High-Density Lipoprotein Metabolism with Rosuvastatin in the Metabolic Syndrome
- (2007) Esther M. M. Ooi et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started